Irisin improves obesity, inflammation, and dyslipidaemia; therefore, the direct insulin-sensitising actions illustrated above exist within a broader picture of overall metabolic improvement, which likely makes a significant additional contribution to the reduction in IR. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.